SCHEMBL4498466

SCHEMBL4498466

Oc1ccc(Nc2ncnc3[nH]cnc23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTBK1 Q5TCY1 2/20 0.59
TTBK2 Q6IQ55 2/20 0.59
ABCG2 Q9UNQ0 1/20 0.49
GAA P10253 5/20 0.48
ALK Q9UM73 2/20 0.46
MKNK1 Q9BUB5 2/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
EGFR P00533 3/20 0.43
KDR P35968 2/20 0.43
FLT3 P36888 2/20 0.43
SLK Q9H2G2 2/20 0.43
FGFR1 P11362 1/20 0.43
DYRK3 O43781 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
PRKCG P05129 1/20 0.43
CDK1 P06493 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30677302 0.84 EGFR (0.54) TTBK1TTBK2MKNK1NPC1RAB9A
SCHEMBL4926094 0.84 EGFR (0.54) TTBK1TTBK2MKNK1NPC1RAB9A
SCHEMBL4923801 0.84 TTBK1 (0.59) TTBK1TTBK2MKNK1MEN1KMT2A
SCHEMBL4922514 0.84 MKNK1 (0.61) TTBK1TTBK2MKNK1MEN1KMT2A
SCHEMBL4921635 0.84 MKNK1 (0.54) TTBK1TTBK2ALKMKNK1MEN1
SCHEMBL891009 0.83 TTBK1 (0.57) TTBK1TTBK2ABCG2EGFRMAP4K4
SCHEMBL10000200 0.83 TTBK1 (0.56) TTBK1TTBK2KDR
SCHEMBL4923486 0.81 TRPV1 (0.45) TTBK1TTBK2MKNK1NPC1RAB9A
SCHEMBL3006952 0.80 BRAF (0.47) TTBK1TTBK2GAAMEN1KMT2A
SCHEMBL4913780 0.80 TTBK1 (0.62) TTBK1TTBK2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576120-B2 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-08-18 US disclosed
EP-1720544-B1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2008-03-19 EP disclosed
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. LES LABORATORATIES SERVIER (FR) 2007-08-23 US disclosed
EP-1720544-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier (FR) 2006-11-15 EP disclosed
WO-2005089747-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. HRH2, HNMT, HRH1 TTBK1 3968/4885TTBK2 3686/4885ABCG2 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.